2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-16637R
    Folic acid (Standard) 59-30-3 98.39%
    Folic acid (Standard) is the analytical standard of Folic acid. This product is intended for research and analytical applications. Folic acid (Vitamin B9) is a orally active essential nutrient from the B complex group of vitamins. Folic acid shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency.
    Folic acid (Standard)
  • HY-A0022A
    Azaphen dihydrochloride monohydrate 63302-99-8 99.94%
    Pipofezine(Azafen or Azaphen) is a potent inhibitor of the reuptake of serotonin.
    Azaphen dihydrochloride monohydrate
  • HY-B0194A
    Tizanidine hydrochloride 64461-82-1 99.93%
    Tizanidine hydrochloride is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.
    Tizanidine hydrochloride
  • HY-113524S
    N-Acetyl-L-aspartic acid-d3 284665-15-2 99.77%
    N-Acetyl-L-aspartic acid-d3 is the deuterium labeled N-Acetyl-L-aspartic acid (HY-113524). N-Acetyl-L-aspartic acid is a derivative of Aspartic acid (HY-N0666) and endogenous compound. N-Acetyl-L-aspartic acid acts as an acetyl donor. N-Acetyl-L-aspartic acid is involved in brain metabolism. N-Acetyl-L-aspartic acid is used in the research of neurodegenerative diseases (such as Canavan disease).
    N-Acetyl-L-aspartic acid-d3
  • HY-W012848
    1-Phenylethanamine 618-36-0 99.14%
    1-Phenylethanamine is a potential central nervous system stimulant and a related compound of β-phenylethylamine. Due to the replacement of its benzene ring with an indole group, its brain glycogenolytic activity is significantly reduced. Therefore, 1-Phenylethanamine can be used to study the impact of the chemical structure of phenylethylamine derivatives on central nervous system activity. In addition, 1-Phenylethanamine can also be used to synthesize the tyrosine kinase (tyrosine kinase) inhibitor CLM3 (HY-164413).
    1-Phenylethanamine
  • HY-103230
    IEM-1460 121034-89-7 ≥98.0%
    IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo.
    IEM-1460
  • HY-132280
    Tirilazad 110101-66-1 98.11%
    Tirilazad is a nonglucocorticoid, 21-aminosteroid that inhibits lipid peroxidation. Tirilazad can attenuate brain or spinal cord injury caused by trauma, stroke, ischemia and reperfusion injury. Tirilazad has antiviral activities against nCoV. Tirilazad is neuroprotective for ischaemic stroke, can be used for subarachnoid hemorrhage research.
    Tirilazad
  • HY-12589
    ZM39923 hydrochloride 1021868-92-7 98.19%
    ZM39923 hydrochloride is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.
    ZM39923 hydrochloride
  • HY-100457
    IC87201 866927-10-8
    IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.
    IC87201
  • HY-102053
    Apimostinel 1421866-48-9 98.69%
    Apimostinel (NRX-1074; AGN-241660) is an orally active NMDA receptor partial agonist.
    Apimostinel
  • HY-109139
    Taminadenant 1337962-47-6 99.84%
    Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response.
    Taminadenant
  • HY-12498
    GV-58 1402821-41-3 99.22%
    GV-58 is a novel N- and P/Q-type calcium (Ca2+) channel agonist with EC50s of 7.21 and 8.81 μM, respectively. GV-58 slows the deactivation of channels, resulting in a large increase in presynaptic Ca2+ entry during activity. GV-58 can be used in lambert-eaton myasthenic syndrome (LEMS) research.
    GV-58
  • HY-14130
    CP 376395 175140-00-8 99.68%
    CP 376395 is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist.
    CP 376395
  • HY-14778
    Retosiban 820957-38-8 98.97%
    Retosiban (GSK221149A) is a potent, selective, and orally active oxytocin receptor antagonist (Ki (hOT) = 0.65 nM, Ki (rOT) = 4.1 nM) with no detectable agonist activity. Retosiban has nanomolar affinity for the oxytocin receptor with >1400-fold selectivity over the closely related vasopressin receptors. Retosiban inhibits spontaneous and induces uterine contractions. Retosiban can be studied in research for preterm labour.
    Retosiban
  • HY-19490
    VQW-765 669770-29-0 99.58%
    VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety.
    VQW-765
  • HY-19740
    BIA 10-2474 1233855-46-3 99.39%
    BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC50 values of 50 to 70mg/kg in various rat brain regions.
    BIA 10-2474
  • HY-101183
    THK5351 1707147-26-9 98.95%
    THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.
    THK5351
  • HY-101860
    GIBH-130 1252608-59-5 99.87%
    GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses the IL-1β secretion by activated microglia (IC50=3.4 nM).
    GIBH-130
  • HY-104028
    BAY 73-6691 794568-92-6 99.84%
    BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitor.
    BAY 73-6691
  • HY-107416
    RHC 80267 83654-05-1 99.41%
    RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC50 of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC50 of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC).
    RHC 80267
Cat. No. Product Name / Synonyms Application Reactivity